Clinical Trials Logo

Clinical Trial Summary

Overdose with potential deadly outcome is a serious problem among opioid abusers, not least in Norway. To save lives, immediate treatment with a μ-opioid antidote such as naloxone is required. The purpose of this study is to explore the pharmacokinetics and pharmacodynamics of naloxone in healthy volunteers under opioid influence.


Clinical Trial Description

Healthy volunteers will be brought into a state of opioid influence in a well-known, short acting, controlled and safe manner using remifentanil. This will create a strong opioid effect inducing a miosis, reduced respiration and reduced sensation to pain, all three strong indicators of opiates. Naloxone will counteract these effects, which can be measured as a change in pupillary size. Blood samples for both naloxone and remifentanil will be also be taken.

Naloxone is a well-known, well-tolerated drug with an excellent safety profile over many decades of use. The formulation used in this trial holds market authorization. Care will be taken not to include opioid users in this study as naloxone would precipitate acute withdrawal. Also possible drug misusers will be excluded as well as people who have access to remifentanil and infusion equipment in their daily work, although the abuse potential of this highly specialised drug is minimal. By weighing syringes before and after discharge the reliability of the dose delivered will be confirmed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02405988
Study type Interventional
Source Norwegian University of Science and Technology
Contact
Status Completed
Phase N/A
Start date April 2015
Completion date February 2016

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04070521 - EEG Monitoring in the Emergency Department
Completed NCT04372238 - The Rhode Island Prescription and Illicit Drug Study N/A
Withdrawn NCT04391192 - Virtual Overdose Response N/A
Completed NCT02924454 - Effects of Lipid Emulsion on the Pharmacokinetic and Pharmacodynamic Properties of Metoprolol. Phase 4
Completed NCT02282306 - Phone Interview to Prevent Recurring Opioid Overdoses N/A
Not yet recruiting NCT01912573 - Nasal Naloxone for Narcotic Overdose Phase 4
Completed NCT04091659 - Use of Virtual Reality for Overdose Management Educational Trainings N/A
Recruiting NCT05517668 - Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose Phase 2
Completed NCT02572089 - Pharmacokinetic Evaluation of Intranasal and Intramuscular Naloxone in Healthy Volunteers Phase 1
Completed NCT02152397 - Safety and Health Intervention Project N/A
Active, not recruiting NCT05096429 - Preventing Overdose Using Information and Data From the Environment N/A
Recruiting NCT03845699 - Development of an Algorithm That Predicts Hypoventilation Due to an Opioid Overdose
Completed NCT03840018 - Effectiveness of a Postal Intervention to Improve the Use of PPI N/A
Recruiting NCT06327061 - Social Network Overdose Prevention and Education Intervention N/A
Completed NCT03087149 - Monitored vs Standard Supplementation of Vitamin D in Preterm Infants N/A
Active, not recruiting NCT05657106 - Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk N/A
Completed NCT02598856 - Bioavailability of Nasal Naloxone and Injected Naloxone Compared Phase 1
Completed NCT02158117 - Bioavailability of a New Formulation of Nasal Naloxone for Prehospital Use Phase 1
Recruiting NCT05146336 - CytOSorb TreatMent Of Critically Ill PatientS Registry
Not yet recruiting NCT02733822 - Buccal Versus Injectable Naloxone: a Phase I Healthy Volunteer Study Phase 1